Compare BioNano Genomics Inc (BNGO) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Five9 Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Five9 Inc trades at $24.76 (market cap $1.96B). The key difference: Five9 Inc is far larger — about 148.5× BioNano Genomics Inc's market cap, and Five9 Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FIVN | |
|---|---|---|
Market Cap | $13.20M | $1.96B |
Sector | Health | Technology |
52-Week High | $4.92 | $29.16 |
52-Week Low | $1.09 | $13.61 |
Enterprise Value | $15.81M | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Five9 (FIVN) trades at $25.81, up 1.53% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, improving profitability, and consistent earnings beats. Recent news includes new executive appointments and AI product launches, alongside ongoing shareholder litigation concerns. Analyst consensus is bullish with a $27.00 price target.
Outlook is positive given earnings momentum and AI-driven growth, but risks include legal overhangs and competitive pressures. The stock offers upside to consensus targets if execution continues, though high valuation multiples require sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
